Luye Pharma Group Ltd., serving as an investment holding company, engages in the global research, development, production, commercialization, and distribution of a diverse portfolio of pharmaceutical products. Their oncology treatments include Lipusu, indicated for ovarian and breast cancer; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injection addressing various cancers and solid tumors. The company also provides Tiandixin, an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections; Yitaida, for acute promyelocytic leukemia and liver cancer; and Lutingnuo, a glutathione injection counteracting toxicity and injuries from ionizing radiation. For metabolic and cardiovascular health, their offerings comprise Xuezhikang, a lipid-regulating drug for hypercholesterolaemia; Beixi, an acarbose capsule for Type 2 diabetes; and Beitangning, a pioglitazone hydrochloride capsule designed to manage blood glucose. In neurology and psychiatry, Luye Pharma provides Maitongna for cerebral edema resulting from trauma or surgery, and for venous reflux disorders. Their pipeline features the Rivastigmine Transdermal Patch for Alzheimer's disease; Fentanyl Transdermal Patch for cancer-related pain; and Buprenorphine Transdermal Patch for chronic pain. They also market Seroquel and Seroquel XR for schizophrenia and manic episodes of bipolar affective disorders, alongside Rykindo, an injectable treatment for schizophrenia. Other specialized products include Nuosen for acute upper digestive tract hemorrhage; Sailimai for the management of diarrhea; the Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for localized swelling; Oukai, for soft tissue swelling and venous edema; and Fengshiye, intended for patients experiencing bone, joint, and limb pain. Beyond traditional pharmaceuticals, the company also extends its operations to include the manufacturing and commercialization of biopharmaceutical products. Luye Pharma Group Ltd. was established in 1994 and is headquartered in Yantai, People's Republic of China.
—
Luye Pharma Group Ltd., serving as an investment holding company, engages in the global research, development, production, commercialization, and distribution of a diverse portfolio of pharmaceutical products. Their oncology treatments include Lipusu, indicated for ovarian and breast cancer; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injection addressing various cancers and solid tumors. The company also provides Tiandixin, an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections; Yitaida, for acute promyelocytic leukemia and liver cancer; and Lutingnuo, a glutathione injection counteracting toxicity and injuries from ionizing radiation. For metabolic and cardiovascular health, their offerings comprise Xuezhikang, a lipid-regulating drug for hypercholesterolaemia; Beixi, an acarbose capsule for Type 2 diabetes; and Beitangning, a pioglitazone hydrochloride capsule designed to manage blood glucose. In neurology and psychiatry, Luye Pharma provides Maitongna for cerebral edema resulting from trauma or surgery, and for venous reflux disorders. Their pipeline features the Rivastigmine Transdermal Patch for Alzheimer's disease; Fentanyl Transdermal Patch for cancer-related pain; and Buprenorphine Transdermal Patch for chronic pain. They also market Seroquel and Seroquel XR for schizophrenia and manic episodes of bipolar affective disorders, alongside Rykindo, an injectable treatment for schizophrenia. Other specialized products include Nuosen for acute upper digestive tract hemorrhage; Sailimai for the management of diarrhea; the Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for localized swelling; Oukai, for soft tissue swelling and venous edema; and Fengshiye, intended for patients experiencing bone, joint, and limb pain. Beyond traditional pharmaceuticals, the company also extends its operations to include the manufacturing and commercialization of biopharmaceutical products. Luye Pharma Group Ltd. was established in 1994 and is headquartered in Yantai, People's Republic of China.
—
Daily adjusted close
Luye Pharma Group Ltd., serving as an investment holding company, engages in the global research, development, production, commercialization, and distribution of a diverse portfolio of pharmaceutical products. Their oncology treatments include Lipusu, indicated for ovarian and breast cancer; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injection addressing various cancers and solid tumors. The company also provides Tiandixin, an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections; Yitaida, for acute promyelocytic leukemia and liver cancer; and Lutingnuo, a glutathione injection counteracting toxicity and injuries from ionizing radiation. For metabolic and cardiovascular health, their offerings comprise Xuezhikang, a lipid-regulating drug for hypercholesterolaemia; Beixi, an acarbose capsule for Type 2 diabetes; and Beitangning, a pioglitazone hydrochloride capsule designed to manage blood glucose. In neurology and psychiatry, Luye Pharma provides Maitongna for cerebral edema resulting from trauma or surgery, and for venous reflux disorders. Their pipeline features the Rivastigmine Transdermal Patch for Alzheimer's disease; Fentanyl Transdermal Patch for cancer-related pain; and Buprenorphine Transdermal Patch for chronic pain. They also market Seroquel and Seroquel XR for schizophrenia and manic episodes of bipolar affective disorders, alongside Rykindo, an injectable treatment for schizophrenia. Other specialized products include Nuosen for acute upper digestive tract hemorrhage; Sailimai for the management of diarrhea; the Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for localized swelling; Oukai, for soft tissue swelling and venous edema; and Fengshiye, intended for patients experiencing bone, joint, and limb pain. Beyond traditional pharmaceuticals, the company also extends its operations to include the manufacturing and commercialization of biopharmaceutical products. Luye Pharma Group Ltd. was established in 1994 and is headquartered in Yantai, People's Republic of China.